<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01450410</url>
  </required_header>
  <id_info>
    <org_study_id>CompHDL2011</org_study_id>
    <nct_id>NCT01450410</nct_id>
  </id_info>
  <brief_title>Nicotinic Acid Composition of HDL and Arterial Endothelium Function in Premature Coronary Heart Disease and High HDL</brief_title>
  <acronym>11MSP011</acronym>
  <official_title>Efecto Del ácido nicotínico Sobre la composición de Las lipoproteínas de Alta Densidad (HDL) y la función Del Endotelio Arterial en Los Pacientes Con cardiopatía isquémica Prematura y Concentraciones Elevadas de Colesterol-HDL</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xavier Pinto Sala</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Universitari de Bellvitge</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with premature ischemic heart disease (PIHD) and elevated levels of HDL-C present an
      altered composition of high-density lipoproteins (HDL) which is associated with a loss of
      their anti-atherogenic effects and of their arterial endothelium function.

      Objectives: To analyse if the treatment with nicotinic acid (NA)/Laropiprant can correct the
      alterations of the HDL composition and endothelial function in patients with PIHD and
      elevated HDL-C.

      Methods: A total of 46 subjects with PIHD who are stable in the 3 months prior to the Study,
      who continue in treatment with statins and have elevated concentrations of HDL-C (HDL-C
      ≥2.0mmol/L in females and ≥1.8mmol/L in males) and an LDL-C &lt;100mg/dL. This is a
      double-blind, randomised Study; after 6 weeks of lifestyle stabilisation, the subjects will
      be treated with NA or placebo for 16 weeks. At the start and end of treatment, HDL
      composition will be studied through density gradient preparative ultracentrifuge separation
      and FBLC (fast protein liquid chromatography) and through the changes in vasodilation induced
      by the endothelium through ultrasound. Primary endpoint: change in the apoA1 content
      associated to treatment. Secondary endpoints: variations in the change of the brachial artery
      diameter with reactive hyperaemia and changes in the content of other lipid and protein
      components of HDL including apoA2, paraoxonase, amyloid A and LCAT. The changes in HDL
      composition and endothelial function will be assessed with an analysis of variance with
      repeated measurements and a 2x2 design.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated (halted prematurely) as recomended by the drug supplier and medical agencies
  </why_stopped>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">May 2013</completion_date>
  <primary_completion_date type="Anticipated">March 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apo A1 of HDL</measure>
    <time_frame>Baseline; 12 weeks</time_frame>
    <description>The amount of Apo A1 as a marker of HDL composition.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Nicotinic Acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nicotinic acid</intervention_name>
    <description>Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.</description>
    <arm_group_label>Nicotinic Acid</arm_group_label>
    <other_name>Tredaptive</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo treatment will last for 12 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Being male or female

          -  Age &gt; 25 years

          -  Have an episode of ischemic heart disease before 55 years in men and in women 65 years

          -  Serum HDL-C above the 90th percentile of the Spanish population: &gt;=2.0mmol/L in women
             and &gt;=1.8mmol/L in men (Gomez-Gerique JA, et al. Med Clin (Barc.). 1999, 113:
             730-735.)

          -  Stable treatment with any statin in the past 6 weeks: simvastatin, atorvastatin,
             rosuvastatin, pravastatin or lovastatin.

        Exclusion Criteria:

          -  Uncontrolled hypercholesterolemia or hypertriglyceridemia, LDL-C &gt;2.6mmol/L or
             triglycerides &gt;2.24mmol/L

          -  Patients with an episode of ischemic heart disease in the last 3 months

          -  Patients suffering from acute or chronic inflammatory diseases in the last 3 months

          -  Treatment with fibrates or omega-3 fatty acids.

          -  Treatment with steroids or immunosuppressive drugs

          -  Patients with a contraindication to Tredaptive (Hypersensitivity to the active
             substances or any of the excipients, significant or unexplained hepatic dysfunction,
             active peptic ulcer, arterial bleeding).

          -  Patients treated with drugs that may interact with Tredaptive (Midazolam).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Pintó, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitari de Bellvitge</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Unitat Funcional de Risc Vascular. Servei Medicina Interna. Hospital Universitari de Bellvitge.</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2011</study_first_submitted>
  <study_first_submitted_qc>October 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2011</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Universitari de Bellvitge</investigator_affiliation>
    <investigator_full_name>Xavier Pinto Sala</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Dyslipemia, HDL composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

